Uridine Triacetate
drugOn this page
Also known as PN-401PN401RG-2133RG2133Triacetate d'uridineTriacetato de uridinaVistogardVistonuridineXuriden2',3',5'-TRI-O-ACETYLURIDINEuridine-triacetateUridine triacetateÊ2';3';5'-Tri-O-acetyluridineUridine triacetateÂ
Summary
Uridine Triacetate (CHEMBL2107381) is an approved small-molecule prodrug (ATC A16AX13); indicated across 5 conditions including exocrine pancreatic carcinoma and gastric neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A16AX13
- Indications: 5 conditions
- Clinical trials: 3
- Chemistry: 370.31 Da · C15H18N2O9
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2107381 |
| Name | Uridine Triacetate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 20058 |
| ChEBI | CHEBI:90914 |
| ATC | A16AX13 |
| Molecular formula | C15H18N2O9 |
| Molecular weight | 370.31 |
| InChIKey | AUFUWRKPQLGTGF-FMKGYKFTSA-N |
SMILES: CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=O)NC2=O)OC(=O)C)OC(=O)C
IUPAC name: [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate
ChEBI definition: An acetate ester that is uracil in which the three hydroxy hydrogens are replaced by acetate group. A prodrug for uridine, it is used for the treatment of hereditary orotic aciduria and for management of fluorouracil toxicity.
Pharmacological roles (ChEBI): prodrug, neuroprotective agent, orphan drug.
Also known as: PN-401, PN401, RG-2133, RG2133, Triacetate d’uridine, Triacetato de uridina, Uridine triacetate, Vistogard, Vistonuridine, Xuriden, URIDINE TRIACETATE, 2’,3’,5’-TRI-O-ACETYLURIDINE
Patent coverage: 520 distinct patent families (1,465 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| exocrine pancreatic carcinoma | 3 | MONDO:0005192 | EFO:0002618 |
| gastric neoplasm | 2 | MONDO:0021085 | MONDO:0001056 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| inborn mitochondrial metabolism disorder | 1 | MONDO:0004069 | MONDO:0044970 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02110147 | PHASE3 | COMPLETED | Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria |
| NCT00060515 | PHASE1 | TERMINATED | RG2133 (2’,3’,5’-Tri-O-Acetyluridine) in Mitochondrial Disease |
| NCT01432301 | Not specified | APPROVED_FOR_MARKETING | Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: exocrine pancreatic carcinoma